hVIVO (LON:HVO) Issues Quarterly Earnings Results

Key Points

• hVIVO reported earnings of GBX (0.29) per share for the quarter, with a net margin of 25.96% and a return on equity of 47.93%.
• The stock price opened at GBX 9 and has experienced a 12-month trading range from GBX 6.50 to GBX 30.
• Analysts have a positive outlook, with an average rating of "Buy" and a price target averaging GBX 28.

hVIVO (LON:HVO - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported GBX (0.29) earnings per share (EPS) for the quarter, Digital Look Earnings reports. hVIVO had a net margin of 25.96% and a return on equity of 47.93%.

hVIVO Stock Performance

Shares of HVO stock opened at GBX 9 on Tuesday. hVIVO has a 12-month low of GBX 6.50 and a 12-month high of GBX 30. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The firm's 50 day moving average is GBX 10.01 and its 200 day moving average is GBX 12.82. The stock has a market capitalization of £61.85 million, a P/E ratio of 580.65 and a beta of 0.97.

Analysts Set New Price Targets

Several research firms have issued reports on HVO. Peel Hunt restated an "add" rating and set a GBX 21 price target on shares of hVIVO in a research report on Tuesday, July 29th. Shore Capital restated a "buy" rating and issued a GBX 35 price objective on shares of hVIVO in a report on Tuesday, July 22nd. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of GBX 28.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.